{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=31",
    "query": {
      "condition": "Solid Tumor Malignancies, Cancer",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 5453,
    "total_pages": 546,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T20:02:34.134Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05701527",
      "title": "A Study of EBC-129 in Advanced Solid Tumours",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "interventions": [
        {
          "name": "EBC-129",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EDDC (Experimental Drug Development Centre), A*STAR Research Entities",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2023-04-28",
      "completion_date": "2026-12-24",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Houston, Texas",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05701527"
    },
    {
      "nct_id": "NCT04743466",
      "title": "Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anxiety Disorder",
        "Depression",
        "Genetic Disorder",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2020-02-13",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743466"
    },
    {
      "nct_id": "NCT02355431",
      "title": "Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors and Hematologic Malignancy",
        "NSCLC (Non-small Cell Lung Carcinoma)"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-12",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2019-03-08",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 1,
      "location_summary": "Ogden, Utah",
      "locations": [
        {
          "city": "Ogden",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02355431"
    },
    {
      "nct_id": "NCT00006047",
      "title": "Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "Oral Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Oral 9-Nitrocamptothecin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2000-06",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2012-09-26",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006047"
    },
    {
      "nct_id": "NCT04730349",
      "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ependymoma",
        "Ewing Sarcoma",
        "High-grade Glioma",
        "Leukemia and Lymphoma",
        "Medulloblastoma",
        "Miscellaneous Brain Tumors",
        "Miscellaneous Solid Tumors",
        "Neuroblastoma",
        "Relapsed, Refractory Malignant Neoplasms",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NKTR-214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 15,
      "start_date": "2021-06-03",
      "completion_date": "2022-06-22",
      "has_results": true,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • St Louis, Missouri",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04730349"
    },
    {
      "nct_id": "NCT05327010",
      "title": "Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Unresectable Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "BET Bromodomain Inhibitor ZEN-3694",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Diagnostic Imaging Testing",
          "type": "PROCEDURE"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2022-11-14",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 35,
      "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 28 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05327010"
    },
    {
      "nct_id": "NCT03573310",
      "title": "A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Solid Tumor, Adult",
        "Non-Hodgkin Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "JNJ-64619178",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2018-07-13",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 4,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03573310"
    },
    {
      "nct_id": "NCT05416710",
      "title": "Universal Germline Testing in the Community",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Invitae's 84 gene multi-cancer panel.",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Invitae Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2022-06-01",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2022-12-07",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 1,
      "location_summary": "Rock Hill, South Carolina",
      "locations": [
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05416710"
    },
    {
      "nct_id": "NCT00708773",
      "title": "Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2006-02",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-04",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708773"
    },
    {
      "nct_id": "NCT05274451",
      "title": "A Study to Investigate LYL797 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "TNBC - Triple-Negative Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
        "Advanced Breast Cancer",
        "Advanced Lung Carcinoma",
        "NSCLC",
        "NSCLC, Recurrent",
        "NSCLC Stage IV",
        "Relapsed Cancer",
        "Relapse/Recurrence",
        "Recurrent Breast Cancer",
        "Recurrent NSCLC",
        "Platinum-resistant Ovarian Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Endometrioid Tumor",
        "High Grade Serous Carcinoma",
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "LYL797",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lyell Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2022-03-29",
      "completion_date": "2024-11-27",
      "has_results": false,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-10-16T20:02:34.134Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05274451"
    }
  ]
}